fda tirzepatide announcement Tirzepatide, FDA, and Compounding: Understanding the Current Landscape ZEPBOUND gets a NEW FDA
Description
Tirzepatide Shown to Tackle Hypogonadism from ENDO 2025: CME INDIA Clinical Pearls: Tirzepatide in Obesity-Associated Hypogonadism @Rssdi_official @IndiaESI @AskDrShashank @banshisaboo @DrAmbrishMithal @dramitaol @KapoorNitinDr @DrShubhaSandill @DrKhushboo_Endo @ Key Takeaways: Metabolic hypogonadism in obese men is an underdiagnosed but clinically significant condition, closely linked with insulin resistance and increased diabetes risk
Others find semaglutide gentler on the digestive system

I Windy H
The starting dosage for weight management is usually lower than that used for diabetes treatment, and it is gradually increased to minimize gastrointestinal side effects
